Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Other Non Operating Income (2021 - 2026)

SAB Biotherapeutics filings provide 6 years of Other Non Operating Income readings, the most recent being $626873.0 for Q1 2026.

  • On a quarterly basis, Other Non Operating Income rose 14.68% to $626873.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $3.2 million, a 27.33% increase, with the full-year FY2025 number at $3.1 million, up 27.77% from a year prior.
  • Other Non Operating Income hit $626873.0 in Q1 2026 for SAB Biotherapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $7.8 million in Q1 2022 to a low of $1527.0 in Q3 2022.
  • Median Other Non Operating Income over the past 5 years was $546627.0 (2025), compared with a mean of $1.1 million.
  • Biggest five-year swings in Other Non Operating Income: tumbled 61.37% in 2022 and later soared 6264.31% in 2023.
  • SAB Biotherapeutics' Other Non Operating Income stood at $32227.0 in 2022, then soared by 948.52% to $337906.0 in 2023, then surged by 153.03% to $854997.0 in 2024, then skyrocketed by 78.44% to $1.5 million in 2025, then crashed by 58.91% to $626873.0 in 2026.
  • The last three reported values for Other Non Operating Income were $626873.0 (Q1 2026), $1.5 million (Q4 2025), and $765881.0 (Q3 2025) per Business Quant data.